ACUT Share Price Performance
US$0.24
-1.81 (-88.34%)
Price US$0.24
Share Pricen/a
AccuStem Sciences, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ACUT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
AccuStem Sciences, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.10
- 100.00%
- -1,679.61%
- -1.5%
About ACUT
- Founded
- 2013
- Employees
- 4
- CEO
- WebsiteView website
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
